“If you plan to be around five or 10 years from now, you have to have a Chinese strategy.” That poignant comment in a BioWorld Today article came from Joshua Boger in 2011. The founder and former CEO of Vertex…
BioWorld Perspectives
news, analysis, debates, commentary and camaraderie related to the development of biotechnology drugs
About this Blog
BioWorld Perspectives is the official blog for news, analysis, debates, commentary and camaraderie related to the development of biotechnology drugs.
Join the Conversation
Sign up for our blog!
Categories
- Accelerated approval (3)
- acquisition (1)
- acute kidney injury (1)
- adcom (3)
- aging (2)
- AIDS (1)
- antibiotics (3)
- Antibody (2)
- Asia (1)
- Autism (1)
- Big pharma (29)
- bioethics (6)
- Biologic (10)
- biopharmaceutical (3)
- Biosimilar (14)
- Biotech conferences (11)
- Biotechnology (101)
- Biotechnology Industry Organization (11)
- BLA (5)
- Books (2)
- Cancer (19)
- Cardiovascular (3)
- China (6)
- chronic fatigue syndrome (3)
- Clinic (5)
- clinical study report (3)
- Clinical Trial (21)
- Clinical Trial Design (3)
- Collaboration (6)
- compassionate use (1)
- Complete Response Letter (4)
- Congress (2)
- corporate tax (1)
- Deals (7)
- Diabetes (1)
- DNA (4)
- Drug Approval (18)
- drug importation (1)
- Drug pricing (4)
- Ebola (1)
- embryonic stem cell research (2)
- emerging markets (3)
- epilepsy (1)
- ethics (2)
- European Medicines Agency (6)
- evolution (1)
- executive salaries (1)
- FDA (33)
- Financing (26)
- Flu (1)
- FOB (2)
- Follow-on biologic (3)
- FTC (1)
- Gene Therapy (5)
- generic (2)
- genetics (6)
- Genomics (9)
- Healthcare reform (5)
- HIV (1)
- human germline engineering (1)
- immunotherapy (4)
- IND (3)
- Initial public offering (1)
- Investigational New Drug Application (4)
- IPO (6)
- License (3)
- M&A (7)
- market capitalization (1)
- Methicillin-resistant Staphylococcus aureus (1)
- mitochondria (1)
- multidrug resistance (2)
- mutation (1)
- National Institutes of Health (2)
- NDA (4)
- neurology (3)
- neuroprostheses (1)
- neuroprosthetic (1)
- New Drug Application (9)
- Obesity (1)
- OIG (1)
- Orphan disease (8)
- pandemic (1)
- partnering (2)
- patent cliff (2)
- Patents (5)
- Patient (2)
- PDUFA (4)
- Personalized medicine (5)
- Pharmaceutical (21)
- Phase I (6)
- Phase II (5)
- Phase III (7)
- Pipeline (6)
- Preclinical (2)
- prostate cancer (1)
- Rare disease (3)
- Reimbursement (10)
- REMS (1)
- RNAi (2)
- SEC (2)
- sequestration (2)
- Series A (1)
- Shareholder value (1)
- siRNA (2)
- social media (1)
- Stem cell (2)
- Summer reading (2)
- Supplemental new drug application (2)
- TB (1)
- traumatic brain injury (1)
- Tuberculosis (2)
- Type 2 Diabetes (1)
- Uncategorized (18)
- Vaccine (5)
- venture captial (9)
- Video (5)
- virus (3)
Recent Posts
- States move forward as SEC lags on crowdfunding rules
- Old dogs and new tricks: The real-world consequences of excluding older adults from drug trials
- Shoppers, start your engines: BioWorld’s 8th Annual Gift Guide
- Death and taxes: Is the corporate tax rate killing the U.S. economy?
- A shot in the dark? ‘Flu’ Manchu-type fears of evil pharma, plus frets over strains and safety, keep too many away from vaccine
Tags
ABH
Amgen Inc
ASCO
BIO
Biotechnology Industry Organization
bioworld
BRIC
Celgene Corp
CEO
China
Clovis Oncology Inc
Cynthia Robbins Roth
Day Four
Day Three
Day Two
Dendreon Corp
DNA
EST
EU
FDA
HCV
HIV
IPO
Janssen Labs
Mama Namibia
Mari Serebrov
MBA
Morgan Healthcare Conference
New York
New York Times
NIH
Nobel Prize
PDUFA
Pfizer Inc
PR
RNA
Roche
ROI
San Diego
San Francisco
Seattle Genetics Inc
SEC
UK
VC
Vivus Inc
Part of Thomson Reuters: thomsonreuters.com | lifesciences.thomsonreuters.com | BioWorld.com | medicaldevicedaily.com
© Copyright 2015 | BioWorld Perspectives
© Copyright 2015 | BioWorld Perspectives